Table 2. Patient, Disease, and Treatment Characteristics.
| Characteristic | Patients, No. (%)a,b | |
|---|---|---|
| Complete data | Missing data | |
| Non–small cell lung cancer | ||
| Total patients, No. | 347 454 | 851 295 |
| Age at diagnosis, median (IQR), y | 69 (62-76) | 69 (61-77) |
| Sex | ||
| Male | 177 594 (51.1) | 451 217 (53.0) |
| Female | 169 860 (48.9) | 400 078 (47.0) |
| Race | ||
| White | 303 607 (87.4) | 720 765 (84.7) |
| Black | 34 565 (9.9) | 95 560 (11.2) |
| Otherc | 9282 (2.7) | 25 802 (3.0) |
| Ethnicity | ||
| Non-Hispanic | 338 785 (97.5) | 758 913 (89.1) |
| Hispanic | 8669 (2.5) | 25 102 (2.9) |
| Charlson-Deyo comorbidity score | ||
| 0 | 184 687 (53.2) | 503 684 (59.2) |
| 1 | 108 556 (31.2) | 229 207 (26.9) |
| 2 | 38 916 (11.2) | 83 537 (9.8) |
| ≥3 | 15 295 (4.4) | 34 867 (4.1) |
| Insurance | ||
| Not insured | 8818 (2.5) | 27 945 (3.3) |
| Private | 92 017 (26.5) | 226 175 (26.6) |
| Medicaid | 19 886 (5.7) | 53 265 (6.3) |
| Medicare | 222 107 (63.9) | 506 860 (59.5) |
| Other government | 4626 (1.3) | 13 691 (1.6) |
| Facility type | ||
| Community | 240 682 (69.3) | 571 663 (67.2) |
| Academic | 106 772 (30.7) | 271 994 (32.0) |
| Tumor | ||
| Year of diagnosis, median (IQR) | 2011 (2009-2013) | 2010 (2008-2013) |
| Overall stage | ||
| I | 145 393 (41.8) | 171 141 (20.1) |
| II | 44 488 (12.8) | 55 601 (6.5) |
| III | 74 441 (21.4) | 174 460 (20.5) |
| IV | 83 073 (23.9) | 375 298 (44.1) |
| Tumor size, cm | ||
| ≤3 | 167 184 (48.1) | 278 361 (32.7) |
| >3 | 179 778 (51.7) | 347 749 (40.8) |
| Lymph nodes involved | ||
| No | 197 933 (57.0) | 287 971 (33.8) |
| Yes | 138 977 (40.0) | 404 504 (47.5) |
| Distant metastasis | ||
| No | 263 796 (75.9) | 445 966 (52.4) |
| Yes | 83 658 (24.1) | 369 411 (43.4) |
| Treatment | ||
| Surgery (primary site) | ||
| No | 174 754 (50.3) | 669 039 (78.6) |
| Yes | 172 700 (49.7) | 178 671 (21.0) |
| Radiotherapy | ||
| No | 223 946 (64.5) | 481 005 (56.5) |
| Yes | 123 508 (35.5) | 359 919 (42.3) |
| Chemotherapy | ||
| No | 207 763 (59.8) | 434 274 (51.0) |
| Yes | 139 691 (40.2) | 376 777 (44.3) |
| Breast cancer | ||
| Total patients, No. | 959 679 | 1 161 096 |
| Age at diagnosis, median (IQR), y | 62 (53-72) | 59 (49-70) |
| Sex | ||
| Male | 8552 (0.9) | 10 465 (0.9) |
| Female | 951 127 (99.1) | 1 150 631 (99.1) |
| Race | ||
| White | 814 602 (84.9) | 947 362 (81.6) |
| Black | 105 594 (11.0) | 137 369 (11.8) |
| Otherc | 39 483 (4.1) | 53 425 (4.6) |
| Ethnicity | ||
| Non-Hispanic | 915 866 (95.4) | 982 844 (84.6) |
| Hispanic | 43 813 (4.6) | 66 997 (5.8) |
| Charlson-Deyo comorbidity score | ||
| 0 | 786 312 (81.9) | 997 133 (85.9) |
| 1 | 137 187 (14.3) | 131 158 (11.3) |
| 2 | 27 511 (2.9) | 24 880 (2.1) |
| ≥3 | 8669 (0.9) | 7925 (0.7) |
| Insurance | ||
| Not insured | 17 384 (1.8) | 25 447 (2.2) |
| Private | 486 495 (50.7) | 626 116 (53.9) |
| Medicaid | 53 951 (5.6) | 70 871 (6.1) |
| Medicare | 392 685 (40.9) | 388 308 (33.4) |
| Other government | 9164 (1.0) | 11 747 (1.0) |
| Facility type | ||
| Community | 684 570 (71.3) | 725 684 (62.5) |
| Academic | 275 109 (28.7) | 341 691 (29.4) |
| Tumor | ||
| Year of diagnosis, median (IQR) | 2012 (2009-2014) | 2010 (2008-2013) |
| Overall stage | ||
| 0 (DCIS) | 133 409 (13.9) | 294 752 (25.4) |
| I | 459 031 (47.8) | 391 027 (33.7) |
| II | 258 213 (26.9) | 254 836 (21.9) |
| III | 78 254 (8.2) | 97 157 (8.4) |
| IV | 30 454 (3.2) | 51 889 (4.5) |
| Tumor size, cm | ||
| ≤2 | 629 447 (65.6) | 610 410 (52.6) |
| >2 | 327 146 (34.1) | 344 006 (29.6) |
| Lymph nodes involved | ||
| No | 731 333 (76.2) | 760 552 (65.5) |
| Yes | 214 178 (22.3) | 230 644 (19.9) |
| Distant metastasis | ||
| No | 926 319 (96.5) | 1 030 431 (88.7) |
| Yes | 33 042 (3.4) | 53 149 (4.6) |
| Treatment | ||
| Surgery (primary site) | ||
| No | 46 302 (4.8) | 109 849 (9.5) |
| Yes | 913 377 (95.2) | 1 046 754 (90.2) |
| Radiotherapy | ||
| No | 433 200 (45.1) | 566 736 (48.8) |
| Yes | 526 479 (54.9) | 572 478 (49.3) |
| Chemotherapy | ||
| No | 634 319 (66.1) | 697 497 (60.1) |
| Yes | 325 360 (33.9) | 395 557 (34.1) |
| Hormonal therapy | ||
| No | 347 616 (36.2) | 487 554 (42.0) |
| Yes | 612 063 (63.8) | 578 864 (49.9) |
| Prostate cancer | ||
| Total patients, No. | 698 468 | 460 167 |
| Age at diagnosis, median (IQR), y | 65 (59-71) | 65 (59-72) |
| Sex | ||
| Male | 698 468 (100.0) | 460 167 (100.0) |
| Race | ||
| White | 579 894 (83.0) | 361 049 (78.5) |
| Black | 99 417 (14.2) | 67 160 (14.6) |
| Otherc | 19 157 (2.7) | 13 501 (2.9) |
| Ethnicity | ||
| Non-Hispanic | 669 071 (95.8) | 366 527 (79.7) |
| Hispanic | 29 397 (4.2) | 20 141 (4.4) |
| Charlson-Deyo comorbidity score | ||
| 0 | 573 655 (82.1) | 379 345 (82.4) |
| 1 | 101 891 (14.6) | 64 092 (13.9) |
| 2 | 17 408 (2.5) | 12 523 (2.7) |
| ≥3 | 5514 (0.8) | 4207 (0.9) |
| Insurance | ||
| Not insured | 11 414 (1.6) | 9344 (2.0) |
| Private | 337 278 (48.3) | 205 477 (44.7) |
| Medicaid | 17 389 (2.5) | 12 835 (2.8) |
| Medicare | 318 328 (45.6) | 201 474 (43.8) |
| Other government | 14 059 (2.0) | 7415 (1.6) |
| Facility type | ||
| Community | 434 953 (62.3) | 278 141 (60.4) |
| Academic | 263 515 (37.7) | 181 155 (39.4) |
| Tumor | ||
| Year of diagnosis, median (IQR) | 2010 (2008-2013) | 2010 (2007-2012) |
| Overall stage | ||
| I | 96 492 (13.8) | 48 900 (10.6) |
| II | 493 798 (70.7) | 266 757 (58.0) |
| III | 73 637 (10.5) | 43 243 (9.4) |
| IV | 34 503 (4.9) | 44 650 (9.7) |
| Lymph node involvement | ||
| No | 650 476 (93.1) | 337 102 (73.3) |
| Yes | 18 464 (2.6) | 19 071 (4.1) |
| Distant metastasis | ||
| No | 677 567 (97.0) | 383 731 (83.4) |
| Yes | 20 862 (3.0) | 34 135 (7.4) |
| Treatment | ||
| Surgery (primary site) | ||
| No | 314 879 (45.1) | 207 399 (45.1) |
| Yes | 383 589 (54.9) | 249 492 (54.2) |
| Radiotherapy | ||
| No | 446 325 (63.9) | 303 962 (66.1) |
| Yes | 252 143 (36.1) | 145 409 (31.6) |
| Chemotherapy | ||
| No | 694 105 (99.4) | 417 776 (90.8) |
| Yes | 4363 (0.6) | 5967 (1.3) |
| Hormonal therapy | ||
| No | 550 765 (78.9) | 323 474 (70.3) |
| Yes | 147 703 (21.1) | 96 039 (20.9) |
Abbreviations: DCIS, ductal carcinoma in situ; IQR, interquartile range.
a
The numbers of patient records with missing or unavailable data for each category are available in eTable 2 in the Supplement.
b
P < .001 for comparisons in all categories with the exception of sex (P = .43).
c
A large number of race categories are recorded in the National Cancer Database. Therefore, consistent with a previous study using data from the National Cancer Database,23 patients of non-White and non-Black races were recoded into the other category.